Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Principal investigators

The primary developers of NAMD 1 were M. Nelson, W. Humphrey, A. Gursoy, A. Dalke and R. Brunner. The primary developers of NAMD 2 were J. Phillips, A. Shinozaki, R. Brunner, N. Krawetz, M. Bhandarkar and A. Gursoy. NAMD development was performed at the National Institutes of Health Resource for Concurrent Biological Computing under the supervision of principal investigators L.V. Kale, R. Skeel, and K. Schulten. This work was... [Pg.480]

Carlson, D. D. (Principal Investigator), Interim Reliability Evaluation Program Procedures Guide, SNL. [Pg.469]

CV of each investigator responsible for the conduct of a trial in a site in the MS concerned (principal investigator)... [Pg.86]

Academic research is mostly performed by single principal investigators within chemical engineering departments... [Pg.26]

Two or three co-principal investigators from different disciplines... [Pg.192]

Many of the frontier research questions outlined in Chapters 4 and 5 can be profitably attacked by adequately supported groups led by a single principal investigator or by multidisciplinary collaborations between small research groups. [Pg.201]

A study of the dermal toxicokinetics of methyl parathion in female rats, sponsored by ATSDR, is being conducted at the University of Mississippi Medical Center. The principal investigator is Dr. Ing K. Ho, Department of Pharmacology and Toxicology, 500 North State Street, Jackson, Mississippi 39216-4505. [Pg.131]

ATSDR is conducting a health study to investigate the lasting health effects of methyl parathion exposure on children. In this study, ATSDR will be testing children in two states, Ohio and Mississippi. The principal Investigator is Dr. Rubina Imtiaz, ATSDR Division of Health Studies, 1600 Clifton Road, Atlanta, Georgia 30333. [Pg.131]

Transparency refers to the degree of openness of the authority in its handling of the product assessment process, and its responsiveness to the concerns of clients and consumers. This area has been evaluated only qualitatively by the principal investigators. [Pg.87]

Kohei Uosaki received his B.Eng. and M.Eng. degrees from Osaka University and his Ph.D. in Physical Chemistry from flinders University of South Australia. He vas a Research Chemist at Mitsubishi Petrochemical Co. Ltd. from 1971 to 1978 and a Research Officer at Inorganic Chemistry Laboratory, Oxford University, U.K. bet veen 1978 and 1980 before joining Hokkaido University in 1980 as Assistant Professor in the Department of Chemistry. He vas promoted to Associate Professor in 1981 and Professor in 1990. He is also a Principal Investigator of International Center for Materials Nanoarchitectonics (MANA) Satellite, National Institute for Materials Science (NIMS) since 2008. His scientific interests include photoelectrochemistry of semiconductor electrodes, surface electrochemistry of single crystalline metal electrodes, electrocatalysis, modification of solid surfaces by molecular layers, and non-linear optical spectroscopy at interfaces. [Pg.337]

The Principal Investigator must ensure that the delegated phases of the study are... [Pg.174]

A final report should be prepared for each regulatory study. In the case of short-term studies, a standardized final reporf accompanied by a sfudy-specific extension may be prepared. Reports of Principal Investigators or scientists involved in the regulatory study should be signed and dated by them. They should contain a Principal Investigator statement and QA statement if the Principal Investigator is not linked to the Study Director organization. [Pg.192]

A quality assurance program statement listing the types of inspections made and their dates, including the phases inspected, and the dates when any inspection results were reported to management, to the Study Director, and to any Principal Investigators, if applicable. This statement would also serve to confirm that the final report reflects the raw data. [Pg.193]

The Study Director/Principal Investigator should ideally discuss all multi-site studies with QA personnel prior to study initiation (or prior to the issue of the protocol amendment if work is not detailed in the protocol). When acting as Study Director, a copy of the current GLP certificates should be requested from sub-contracted facilities and should be retained in QA. [Pg.194]


See other pages where Principal investigators is mentioned: [Pg.12]    [Pg.1031]    [Pg.3]    [Pg.148]    [Pg.70]    [Pg.81]    [Pg.84]    [Pg.46]    [Pg.90]    [Pg.192]    [Pg.192]    [Pg.200]    [Pg.207]    [Pg.599]    [Pg.628]    [Pg.50]    [Pg.108]    [Pg.53]    [Pg.111]    [Pg.174]    [Pg.174]    [Pg.174]    [Pg.175]    [Pg.175]    [Pg.176]    [Pg.176]    [Pg.176]    [Pg.177]    [Pg.177]    [Pg.179]    [Pg.179]    [Pg.180]    [Pg.193]    [Pg.194]    [Pg.195]    [Pg.195]    [Pg.202]   
See also in sourсe #XX -- [ Pg.220 ]

See also in sourсe #XX -- [ Pg.72 ]

See also in sourсe #XX -- [ Pg.194 , Pg.204 , Pg.214 ]

See also in sourсe #XX -- [ Pg.199 , Pg.204 ]




SEARCH



Pharmacist as Principal Investigator (ACCP) American College of Clinical Pharmacy

Principal investigator, clinical pharmacist

Study Director and Principal Investigator

© 2024 chempedia.info